7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Hemolytic anemia following rasburicase administration: a review of published reports.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Tumor lysis syndrome (TLS) is a potentially lethal complication of anticancer treatment. It is caused by the rapid death of malignant cells after initiation of cytotoxic therapy and is typically observed in patients with bulky or highly proliferative malignancies. Currently, rasburicase is one of the recommended therapies for this oncologic emergency. Although this drug is generally well tolerated among patients, there have been several reports of hemolytic anemia following rasburicase infusions. With drug-induced hemolytic anemia, the condition usually resolves shortly after the offending agent is discontinued. However, anemia that is prolonged or severe can lead to problems such as splenomegaly and rapid heart rate. This paper will review primary literature identified through PubMed, International Pharmaceutical Abstracts, and Embase concerning the incidence of hemolytic anemia with rasburicase use. From the available data, the occurrence of hemolytic anemia will be discussed.

          Related collections

          Author and article information

          Journal
          J Pediatr Pharmacol Ther
          The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG
          Pediatric Pharmacy Advocacy Group
          1551-6776
          1551-6776
          March 13 2015
          : 19
          : 4
          Affiliations
          [1 ] Target, Fort Wayne, Indiana.
          [2 ] Christy Houston Foundation Drug Information Center, Belmont University College of Pharmacy, Nashville, Tennessee ; Department of Pharmaceutical, Social and Administrative Sciences, Belmont University College of Pharmacy, Nashville, Tennessee.
          Article
          10.5863/1551-6776-19.4.310
          4341417
          25762877
          89e22cef-3c2f-405d-a9e7-4a1716ac4b17
          History

          hemolytic anemia,rasburicase,tumor lysis syndrome
          hemolytic anemia, rasburicase, tumor lysis syndrome

          Comments

          Comment on this article